Nobel Prize in Physiology or Medicine 2026 Awarded for Optogenetics Breakthroughs

The 2026 Nobel Prize in Physiology or Medicine was awarded jointly to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries that made optogenetics possible, a light-based method that lets scientists switch specific nerve cells on or off and test how brain circuits drive behavior. The official citation from the Nobel Assembly at Karolinska Institutet was “for their discoveries concerning light-gated ion channels and optogenetics.”

Karolinska announced the award on Oct. 5 and said the prize carries 12 million Swedish kronor, to be shared among the three laureates. Deisseroth is affiliated with the Howard Hughes Medical Institute and Stanford University, where he is a professor of bioengineering and of psychiatry and behavioral sciences. Hegemann is Hertie Senior Professor of Neuroscience at Humboldt University of Berlin. Nagel is a professor at the University of Würzburg.

The prize recognizes a scientific sequence that began not in the brain, but in algae. Hegemann and Nagel were central to the discovery and characterization of channelrhodopsin, a light-sensitive ion-channel protein from the green alga Chlamydomonas reinhardtii. A landmark paper describing channelrhodopsin-1 was published in Science in 2002, establishing the basis for using light-gated proteins to control cell activity.

Deisseroth and collaborators then turned that basic finding into a practical neuroscience method. In 2005, they showed that mammalian neurons genetically targeted to carry these proteins could be controlled with pulses of light on millisecond timescales. Follow-up work by 2007 demonstrated robust use in living, behaving animals, helping transform the approach from a promising concept into a widely used experimental tool.

In plain terms, optogenetics combines genetics and light to control defined groups of cells. Before it, neuroscientists could often record brain activity or broadly stimulate tissue, but they had fewer precise ways to test whether a particular set of neurons actually caused a behavior, memory or emotional response. Optogenetics changed that by giving researchers fast, cell-type-specific control in living brains.

Karolinska said the method has made it possible to show how nerve cells shape memories, feelings and behaviors in the living brain, and that it has become a major tool for mapping brain circuits and studying neurological and psychiatric disorders. “Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said in remarks released by Karolinska.

The award also reflects how broadly the work has been recognized across institutions tied to the laureates. Stanford, Humboldt University and the University of Würzburg separately confirmed the Nobel announcement and highlighted the roles each scientist played in building the field: the discovery of the light-gated ion channels in algae, and the adaptation of those proteins into a method for controlling neurons in mammals.

Optogenetics remains primarily a research tool rather than a standard medical treatment. But it has begun to reach early human testing for vision restoration. A 2021 Nature Medicine case report described partial recovery of visual function in a blind patient after optogenetic therapy, offering a proof of concept for clinical use while underscoring that the field’s main impact so far has been in basic science. As Deisseroth said in a Stanford statement, “Optogenetics is an engine for discovery.”